NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









NeuroGenesis

NeuroGenesis

Private
Rochester, New YorkHealthcare & Life Scienceshttps://neurogenesis-cell.com/

Last Round

Grant

Aug 5, 2025

Total Funding Raised

$10M

Company Overview

NeuroGenesis is a clinical-stage cellular therapy company that develops treatments for neurodegenerative diseases such as multiple sclerosis and amyotrophic lateral sclerosis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cell therapyautologous stem cellregenerative medicineneurodegenerative diseaseamyotrophic lateral sclerosismultiple sclerosisALSMSremyelinationintrathecal deliveryclinical-stage biotechbiopharmapersonalized medicinebiofactory cells

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NeuroGenesis Comps

Public and private peers based on sector, stage, and business model.

NeuroGenesis comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

NeuroGenesis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 5, 2025
Series AMar 11, 2022

Key People

Founding team and executive leadership

Ibrahim Kassis

Co-Founder - Chief Scientist - Chief Technology Officer

Founding Team

Tal Gilat

Founder & CEO

Founding Team

Nir Netzer

COO

Executive Team

NeuroGenesis Investors

Notable investors and investment history

NeuroGenesis investors
InvestorRounds
Excell PartnersSeries A
National MS SocietyGrant
Counterpoint Global (Morgan Stanley)Series A
Rhodium VenturesSeries A
New York VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 1, 2025

    Monthly visitors grew 664% MoM, reaching 1.2K.

NeuroGenesis Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NeuroGenesis Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NeuroGenesis's valuation, stock price, and market status.

Firmographic Details

HeadquartersRochester, New York
Employee Range14
Year Founded2018
Last FundingAug 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.